title: Pulmonary follow-up 2.5 years after a randomized, controlled, multiple dose bovine surfactant study of preterm newborn infants.
abstract: Forty-seven preterm infants, who were previously enrolled in a prospective, randomized, blinded study at birth to assess the effects of multiple doses of exogenous bovine surfactant to prevent respiratory distress syndrome, underwent lung function evaluation and review of their medical histories at 2 1/2 years of age. During their initial hospitalization there were no differences between the 17 control infants and the 30 surfactant-treated infants in the duration of ventilator or oxygen therapy and the incidence of bronchopulmonary dysplasia. At the follow-up both groups were similar in chronological and corrected ages, weights, lengths, and sex ratios and there were no differences in the occurrence of allergy, asthma, bronchiolitis, eczema, pneumonia, and wheezing. In addition, there was no significant difference regarding the incidence of chest illnesses lasting either 3 or 7 days and in the total number of required rehospitalizations. Functional residual capacity (FRC), tidal volume (VT/kg), compliance (Crs/kg), resistance (Rrs), and time constant of the respiratory system were not significantly different between the two groups at 2 1/2 years of age. We conclude that bovine surfactant, when given during the neonatal period, has little long-term effect on lung function. Neonatal bovine surfactant therapy neither improves nor produces any adverse effects on the developing respiratory system.
authors.affiliation: Division of Neonatology, Minneapolis Children's Medical Center, Minnesota 55404.
authors.forename: R J
authors.initials: RJ
authors.lastname: Couser
authors.forename: T B
authors.initials: TB
authors.lastname: Ferrara
authors.forename: W
authors.initials: W
authors.lastname: Wheeler
authors.forename: J
authors.initials: J
authors.lastname: McNamara
authors.forename: B
authors.initials: B
authors.lastname: Falde
authors.forename: K
authors.initials: K
authors.lastname: Johnson
authors.forename: R E
authors.initials: RE
authors.lastname: Hoekstra
mesh_terms: D000818:Animals; D001688:Biological Products; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D008171:Lung Diseases / Q000453:epidemiology / Q000503:physiopathology; D008297:Male; D010100:Oxygen / Q000627:therapeutic use; D011446:Prospective Studies; D011663:Pulmonary Surfactants / Q000494:pharmacology / Q000627:therapeutic use*; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000503:physiopathology / Q000517:prevention & control*; D012129:Respiratory Function Tests; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001688:Biological Products; D011663:Pulmonary Surfactants; C072197:beractant; D010100:Oxygen